secwatch.observer — SEC 8-K summary
======================================

Issuer:     89bio, Inc. (—)
CIK:        0001785173
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001193125-24-091945
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

89bio enters $135M agreement with BiBo to build pegozafermin production facility
--------------------------------------------------------------------------------

- Collaboration agreement with BiBo to construct a production facility for pegozafermin commercial supply.
- 89bio to pay $135M total; 45% due in Q3 2024, remainder on milestone achievements.
- Facility located in Lin-gang Special Area, Shanghai Pilot Free Trade Zone.
- Work order for commercial supply under existing MSA expected before facility operations.
- Negotiated discount on commercial supply until payment recouped.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785173/000119312524091945/0001193125-24-091945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785173/000119312524091945/d818064d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-091945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer